Related Experiment Video
Updated: Jul 5, 2026
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Effect of CKBM on prostate cancer cell growth in vitro and in vivo
Edgar S L Liu1, Sharon C W Luk, Eric T Y Leung
1CK Life Sciences International Inc., Tai Po Industrial Estate, Hong Kong. edgar.liu@ck-lifesciences.com
Abstract:
Prostate carcinoma and metastasis are common among male subjects worldwide. CKBM is a drug product targeting prostate cancer in multiple ways. Prostate cancer cell lines PC3 and DU145 were treated with CKBM. The effect of CKBM on the cell's viability, cell cycle, adhesive and invasive properties and its growth in an animal model were assessed. Results indicated that CKBM inhibited PC3 and DU145 cell growth in vitro at IC(50 )values 3.923 and 4.697% respectively, and it brought about cell cycle arrest at G2/M phase. CKBM also attenuated DU145 cells to invade and adhere to extracellular matrices including Matrigel, laminin, fibronectin and collagen IV. Moreover, PC3 tumor xenograft growth was inhibited by over 60% after 28-day of 0.2, 0.4 or 0.8 ml/day CKBM treatment. The present study indicates that CKBM is effective against prostate cancer cell growth in vitro and in vivo. Further studies are required to elucidate its mechanism of action.
Insights
CKBM effectively inhibits prostate cancer cell growth both in vitro and in vivo. This drug candidate demonstrated significant anti-cancer effects, including reduced cell viability and tumor growth in preclinical models.
Area of Science:
- Oncology
- Pharmacology
Background:
- Prostate carcinoma is a prevalent malignancy in males globally.
- Metastasis significantly complicates prostate cancer treatment and prognosis.
- CKBM is a novel drug product developed to target prostate cancer through multiple mechanisms.
Purpose of the Study:
- To evaluate the efficacy of CKBM against prostate cancer cell lines (PC3 and DU145) in vitro.
- To assess the impact of CKBM on tumor growth in a preclinical animal model.
- To investigate CKBM's effects on cell viability, cell cycle, adhesion, and invasion.
Main Methods:
- Prostate cancer cell lines (PC3, DU145) were treated with CKBM.
- In vitro assays measured cell viability, cell cycle progression, adhesion, and invasion.
- In vivo studies utilized PC3 tumor xenografts treated with varying doses of CKBM over 28 days.
Main Results:
- CKBM inhibited PC3 and DU145 cell growth in vitro with IC50 values of 3.923% and 4.697%, respectively.
- CKBM induced cell cycle arrest at the G2/M phase and reduced the invasive and adhesive properties of DU145 cells.
- PC3 tumor xenograft growth was suppressed by over 60% following 28 days of CKBM treatment.
Conclusions:
- CKBM exhibits significant anti-cancer activity against prostate cancer in both in vitro and in vivo models.
- The drug demonstrates potential as a therapeutic agent for prostate cancer.
- Further research is warranted to fully elucidate the mechanism of action of CKBM.
